Creating a registry for patients with neuroendocrine cervical cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to collect and organize data on patients diagnosed with neuroendocrine carcinoma of the cervix, including various histologic subtypes. It will gather both retrospective and prospective information regarding disease characteristics, treatment regimens, and patient outcomes over a period of up to 10 years. The data will be stored in a secure repository to facilitate future research and enhance understanding of the disease's impact on patient health. By correlating clinical data with outcomes, the study seeks to improve knowledge and treatment strategies for this rare cancer.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with a personal history of cervical cancer with any portion of neuroendocrine component (including mixed tumors) of the following histologic subtypes:

  * Small cell neuroendocrine carcinoma
  * Large cell neuroendocrine carcinoma
  * Undifferentiated high-grade neuroendocrine carcinoma
* Patients may be in any stage of treatment, surveillance or recurrence at the time of initial participation in the study
* Patients with all stages of disease are considered eligible
* Patients who do not speak English can be eligible if accompanied by an institutional interpreter
* Patients who are receiving or have received treatment at any facility, including but not limited to M. D. Anderson Cancer Center are eligible
* Patient may be residents of any country and be of any ethnic background
* Patients who request to participate in the study, regardless of the method by which they learned of it, are eligible to participate, including, but not limited to patients who seek participation via the website
* Next of kin or legal authorized representatives of patients who are deceased but had a history of neuroendocrine carcinoma (NEC) of the cervix are eligible to participate
* Next of kin or legal authorized representatives of patients must read and speak English

Exclusion Criteria:

* Patients with other histologic subtypes of NEC of the cervix including typical and atypical carcinoid tumors

Where it's running

• M D Anderson Cancer Center
  Houston, Texas, United States Recruiting

Study contacts

• Principal investigator: Larissa A. Meyer — M.D. Anderson Cancer Center
• Study coordinator: Larissa A. Meyer, MD
• Email: lmeyer@mdanderson.org
• Phone: 713-745-0973

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Personalized vaccine combined with pembrolizumab for advanced solid tumors

  This study is testing a new personalized cancer vaccine combined with pembrolizumab to see if it helps people with advanced solid tumors fight their cancer better.

  Recruiting Phase 1/2 Mayo Clinic · Jacksonville, Florida · NCT05269381

• Combining talazoparib with radiation therapy for recurrent gynecologic cancers

  This study is testing if combining a drug called talazoparib with radiation therapy can safely help people with recurrent gynecologic cancers feel better.

  Recruiting at 2 sites Phase 1 M.D. Anderson Cancer Center · Baltimore, Maryland and 1 other locations · NCT03968406

• Blended e-Health Program to Help Women with Breast or Gynecologic Cancer Manage Fear of Cancer Progression

  This trial tests a blended online and group program to see if it helps women with breast or gynecologic cancer feel less fear that their cancer could grow or spread.

  Recruiting at 11 sites City of Hope Medical Center · Arcadia, California and 10 other locations · NCT07741968

• Short-course (hypofractionated) versus standard radiotherapy with cisplatin and brachytherapy for locally advanced cervical cancer in Uganda

  This trial tests whether a shorter, higher-dose radiotherapy schedule plus cisplatin and brachytherapy works as well and causes no more serious side effects than the usual longer schedule for women in Uganda with stage IB3–IIIC cervical cancer.

  Recruiting Phase 2 Uganda Cancer Institute · Kampala, Kampala · NCT07276360

• Phase I testing of 225Ac-ETN029 for advanced DLL3-positive tumors

  This trial will test 225Ac-ETN029, with 111In-ETN029 used for imaging, to see if the treatment is safe, tolerable, and shows early anti-tumor activity in adults with advanced DLL3-positive neuroendocrine cancers.

  Recruiting at 8 sites Phase 1 Novartis · Iowa City, Iowa and 7 other locations · NCT07006727

• Predicting how tumors respond to immune therapies using a live diagnostic platform

  This study is testing a new way to predict how well immune therapies will work for patients with different types of solid tumors, including early-stage and metastatic cancers.

  Recruiting at 3 sites Mayo Clinic · Phoenix, Arizona and 2 other locations · NCT06349642

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.